Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

2.

Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers.

Fukagawa D, Sugai T, Osakabe M, Suga Y, Nagasawa T, Itamochi H, Sugiyama T.

Oncotarget. 2018 Jun 8;9(44):27514-27524. doi: 10.18632/oncotarget.25518. eCollection 2018 Jun 8.

3.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 May 15. doi: 10.1038/s41388-018-0300-6. [Epub ahead of print]

4.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
5.

Kir Channel Blockages by Proflavine Derivatives via Multiple Modes of Interaction.

Inanobe A, Itamochi H, Kurachi Y.

Mol Pharmacol. 2018 Jun;93(6):592-600. doi: 10.1124/mol.117.111377. Epub 2018 Apr 12.

PMID:
29650538
6.

Measurement of endometrial thickness in premenopausal women in office gynecology.

Tsuda H, Ito YM, Todo Y, Iba T, Tasaka K, Sutou Y, Hirai K, Dozono K, Dobashi Y, Manabe M, Sakamoto T, Yamamoto R, Ueda K, Akatsuka M, Kiyozuka Y, Nagai N, Imai M, Kobiki K, Fujita H, Itamochi H, Oshita T, Kawarada T, Hatae M, Yokoyama Y.

Reprod Med Biol. 2017 Sep 16;17(1):29-35. doi: 10.1002/rmb2.12062. eCollection 2018 Jan.

7.

Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.

Tamura R, Yoshihara K, Saito T, Ishimura R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda K, Sato S, Itamochi H, Motoyama T, Aoki Y, Okuda S, Casingal CR, Nakaoka H, Inoue I, Verhaak RGW, Komatsu M, Enomoto T.

Oncogenesis. 2018 Jan 23;7(1):4. doi: 10.1038/s41389-017-0018-2.

8.

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target.

Tsang TY, Wei W, Itamochi H, Tambouret R, Birrer MJ.

Oncotarget. 2017 Aug 4;8(57):96482-96495. doi: 10.18632/oncotarget.19946. eCollection 2017 Nov 14.

9.

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J.

Mol Ther. 2017 Oct 4;25(10):2427. doi: 10.1016/j.ymthe.2017.09.018. Epub 2017 Sep 23. No abstract available.

10.

Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.

Chiba Y, Sato S, Itamochi H, Yoshino N, Fukagawa D, Kawamura H, Suga Y, Kojima-Chiba A, Muraki Y, Sugai T, Sugiyama T.

Int J Gynecol Cancer. 2017 Oct;27(8):1666-1674. doi: 10.1097/IGC.0000000000001081.

PMID:
28786875
11.

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.

Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T.

Br J Cancer. 2017 Aug 22;117(5):717-724. doi: 10.1038/bjc.2017.228. Epub 2017 Jul 20.

12.

Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.

Komatsu H, Oishi T, Itamochi H, Shimada M, Sato S, Chikumi J, Sato S, Nonaka M, Sawada M, Wakahara M, Umekita Y, Harada T.

Int J Gynecol Cancer. 2017 Sep;27(7):1325-1332. doi: 10.1097/IGC.0000000000001027.

PMID:
28557832
13.

Surgical management of non-invasive uterine clear cell carcinoma.

Sugiyama T, Takeuchi S, Itamochi H.

J Gynecol Oncol. 2017 Jul;28(4):e55. doi: 10.3802/jgo.2017.28.e55. No abstract available.

14.

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J.

Mol Ther. 2017 Jan 4;25(1):259-273. doi: 10.1016/j.ymthe.2016.10.012. Epub 2017 Jan 4.

15.

Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.

Chiba Y, Sato S, Itamochi H, Suga Y, Fukagawa T, Oumi N, Oishi T, Harada T, Sugai T, Sugiyama T.

Hum Cell. 2017 Apr;30(2):140-148. doi: 10.1007/s13577-016-0154-6. Epub 2016 Nov 26.

PMID:
27889902
16.

A Multi-Institutional Feasibility Study on the Use of Automated Screening Systems for Quality Control Rescreening of Cervical Cytology.

Sugiyama Y, Sasaki H, Komatsu K, Yabushita R, Oda M, Yanoh K, Ueda M, Itamochi H, Okugawa K, Fujita H, Tase T, Nakatani E, Moriya T.

Acta Cytol. 2016;60(5):451-457. Epub 2016 Sep 28.

17.

Fertility-sparing surgery for uterine cervical cancer.

Sato S, Itamochi H, Sugiyama T.

Future Oncol. 2016 Oct;12(20):2345-55. doi: 10.2217/fon-2016-0260. Epub 2016 Aug 31. Review.

PMID:
27578750
18.

Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.

Shimada M, Sato S, Oishi T, Itamochi H, Kigawa J, Takeshima N, Aoki D, Aoki Y, Nambu Y, Ochiai K.

Int J Clin Oncol. 2016 Oct;21(5):969-974. Epub 2016 May 3.

PMID:
27142771
19.

Profile of farletuzumab and its potential in the treatment of solid tumors.

Sato S, Itamochi H.

Onco Targets Ther. 2016 Mar 7;9:1181-8. doi: 10.2147/OTT.S98242. eCollection 2016. Review.

20.

Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Sato S, Itamochi H, Oumi N, Chiba Y, Oishi T, Shimada M, Sato S, Chikumi J, Nonaka M, Kudoh A, Komatsu H, Harada T, Sugiyama T.

Hum Cell. 2016 Oct;29(4):181-7. doi: 10.1007/s13577-016-0138-6. Epub 2016 Mar 9.

PMID:
26960408
21.

Cytoplasmic Maspin Expression Correlates with Poor Prognosis of Patients with Adenocarcinoma of the Uterine Cervix.

Nosaka K, Horie Y, Shiomi T, Itamochi H, Oishi T, Shimada M, Sato S, Sakabe T, Harada T, Umekita Y.

Yonago Acta Med. 2015 Dec;58(4):151-6. Epub 2015 Dec 18.

22.

Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia.

Kudoh A, Sato S, Itamochi H, Komatsu H, Nonaka M, Sato S, Chikumi J, Shimada M, Oishi T, Kigawa J, Harada T.

Int J Clin Oncol. 2016 Jun;21(3):580-7. doi: 10.1007/s10147-015-0929-x. Epub 2015 Nov 27.

PMID:
26614089
23.

Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.

Creixell P, Schoof EM, Simpson CD, Longden J, Miller CJ, Lou HJ, Perryman L, Cox TR, Zivanovic N, Palmeri A, Wesolowska-Andersen A, Helmer-Citterich M, Ferkinghoff-Borg J, Itamochi H, Bodenmiller B, Erler JT, Turk BE, Linding R.

Cell. 2015 Sep 24;163(1):202-17. doi: 10.1016/j.cell.2015.08.056. Epub 2015 Sep 17.

24.

Apparent diffusion coefficient (ADC) measurement in ovarian tumor: Effect of region-of-interest methods on ADC values and diagnostic ability.

Mukuda N, Fujii S, Inoue C, Fukunaga T, Tanabe Y, Itamochi H, Ogawa T.

J Magn Reson Imaging. 2016 Mar;43(3):720-5. doi: 10.1002/jmri.25011. Epub 2015 Jul 22.

PMID:
26201495
25.

Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing.

Oumi N, Itamochi H, Komatsu H, Oishi T, Shimada M, Sato S, Chikumi J, Sato S, Nonaka M, Kudoh A, Harada T.

Hum Cell. 2016 Jan;29(1):46-51. doi: 10.1007/s13577-015-0120-8. Epub 2015 Jun 13.

PMID:
26070481
26.

Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.

Itamochi H, Oumi N, Oishi T, Taniguchi F, Shoji T, Fujiwara H, Sugiyama T, Suzuki M, Kigawa J, Harada T.

Int J Gynecol Cancer. 2015 May;25(4):570-6. doi: 10.1097/IGC.0000000000000414.

PMID:
25756405
27.

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.

Itamochi H, Oumi N, Oishi T, Shoji T, Fujiwara H, Sugiyama T, Suzuki M, Kigawa J, Harada T.

Int J Clin Oncol. 2015 Oct;20(5):967-73. doi: 10.1007/s10147-015-0811-x. Epub 2015 Mar 6.

PMID:
25744580
28.

Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).

Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; Gynecologic Oncology Study Group of the Japan Clinical Oncology Group.

Gynecol Oncol. 2015 Apr;137(1):34-9. doi: 10.1016/j.ygyno.2015.01.548. Epub 2015 Feb 7.

PMID:
25662625
29.

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M.

PLoS One. 2015 Feb 6;10(2):e0116977. doi: 10.1371/journal.pone.0116977. eCollection 2015.

30.

Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Sato S, Itamochi H.

Ther Adv Med Oncol. 2014 Nov;6(6):293-304. doi: 10.1177/1758834014544891.

31.

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289. Review. Erratum in: Int J Gynecol Cancer. 2015 May;25(4):721. Mezzazanica, Delia [corrected to Mezzanzanica, Delia].

PMID:
25341576
32.

Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.

Miyata K, Yotsumoto F, Nam SO, Odawara T, Manabe S, Ishikawa T, Itamochi H, Kigawa J, Takada S, Asahara H, Kuroki M, Miyamoto S.

Cancer Med. 2014 Oct;3(5):1159-69. doi: 10.1002/cam4.301. Epub 2014 Jul 24.

33.

Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy.

Deura I, Shimada M, Hirashita K, Sugimura M, Sato S, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J.

Int J Clin Oncol. 2015 Jun;20(3):556-60. doi: 10.1007/s10147-014-0724-0. Epub 2014 Jul 4.

PMID:
24993674
34.

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.

Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.

Oncol Rep. 2014 Aug;32(2):553-8. doi: 10.3892/or.2014.3268. Epub 2014 Jun 13.

PMID:
24927217
35.

Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.

Takeshima N, Matoda M, Abe M, Hirashima Y, Kai K, Nasu K, Takano M, Furuya K, Sato S, Itamochi H, Tsubamoto H, Hasegawa K, Terao K, Otsuki T, Kuritani K, Ito K.

Support Care Cancer. 2014 Nov;22(11):2891-8. doi: 10.1007/s00520-014-2280-6. Epub 2014 May 14.

PMID:
24825735
36.

Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.

Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.

Int J Gynecol Cancer. 2014 Mar;24(3):444-53. doi: 10.1097/IGC.0000000000000091.

PMID:
24552895
37.

Insulin-like growth factor I regulates the expression of isoforms of Wilms' tumor 1 gene in breast cancer.

Tuna M, Itamochi H.

Tumori. 2013 Nov-Dec;99(6):715-22. doi: 10.1700/1390.15461.

PMID:
24503796
38.

Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.

Itamochi H, Nishimura M, Oumi N, Kato M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, Kigawa J, Harada T.

Int J Gynecol Cancer. 2014 Jan;24(1):61-9. doi: 10.1097/IGC.0000000000000014.

PMID:
24362713
39.

Predicting time to ovarian carcinoma recurrence using protein markers.

Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG.

J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. Erratum in: J Clin Invest. 2013 Dec 2;123(12):5410.

40.

Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Shimada M, Itamochi H, Kigawa J.

Cancer Manag Res. 2013 May 8;5:67-76. doi: 10.2147/CMAR.S35785. Print 2013.

41.

Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.

Taniguchi F, Itamochi H, Harada T, Terakawa N.

Int J Gynecol Cancer. 2013 Jun;23(5):791-6. doi: 10.1097/IGC.0b013e31828f38c4.

PMID:
23640291
42.

Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy.

Uegaki K, Shimada M, Sato S, Deura I, Naniwa J, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J.

Int J Clin Oncol. 2014 Apr;19(2):348-53. doi: 10.1007/s10147-013-0559-0. Epub 2013 Apr 17.

PMID:
23592280
43.

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Itamochi H, Kato M, Nishimura M, Oumi N, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T.

Hum Cell. 2013 Sep;26(3):121-7. doi: 10.1007/s13577-013-0062-y. Epub 2013 Feb 21.

PMID:
23430509
44.

Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.

Itamochi H, Kato M, Nishimura M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T.

Hum Cell. 2012 Dec;25(4):111-5. doi: 10.1007/s13577-012-0048-1. Epub 2012 Dec 30.

PMID:
23274876
45.

[Molecular targeted therapies for epithelial ovarian cancer].

Itamochi H, Kigawa J.

Nihon Rinsho. 2012 Jun;70 Suppl 4:622-7. Japanese. No abstract available.

PMID:
23156321
46.

Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, Tanimoto H, Noma J, Hayase R, Murakami A, Fujimoto H, Kanamori Y, Kitada F, Shitsukawa K, Nagaji M, Minagawa Y, Fujiwara M, Kigawa J.

Int J Clin Oncol. 2013 Dec;18(6):1107-13. doi: 10.1007/s10147-012-0483-8. Epub 2012 Oct 17.

PMID:
23073623
47.

Clinical trials and future potential of targeted therapy for ovarian cancer.

Itamochi H, Kigawa J.

Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28. Review.

PMID:
22926640
48.

Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.

Nonaka M, Itamochi H, Kawaguchi W, Kudoh A, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T.

Int J Gynecol Cancer. 2012 Jul;22(6):922-9. doi: 10.1097/IGC.0b013e31824f0b13.

PMID:
22672985
49.

Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.

Shimada M, Fujiwara H, Sato S, Oishi T, Itamochi H, Machida S, Takei Y, Harada T, Suzuki M, Kigawa J.

Cancer Chemother Pharmacol. 2012 Jul;70(1):33-8. doi: 10.1007/s00280-012-1885-z. Epub 2012 May 18.

PMID:
22610355
50.

Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.

Minagawa Y, Shimada M, Itamochi H, Sato S, Sato S, Okada M, Kitada F, Kigawa J.

Gynecol Obstet Invest. 2012;73(4):272-6. doi: 10.1159/000332368. Epub 2012 Mar 1.

PMID:
22378216

Supplemental Content

Loading ...
Support Center